Read by QxMD icon Read


Ws Lane, James Weatherall, Jens Gundgaard, Richard F Pollock
No abstract text is available yet for this article.
March 21, 2018: Journal of Medical Economics
Muhammad Ali Karamat, Shujah Dar, Srikanth Bellary, Abd A Tahrani
INTRODUCTION: To assess the real-life clinical benefits and cost implications of switching from another basal insulin to insulin degludec (degludec) in patients with type 1 diabetes (T1D) on basal-bolus regimens with recurrent hypoglycemia and/or hypoglycemia unawareness. METHODS: Patients with T1D who were aged ≥ 18 years, were on a basal-bolus regimen, and had switched to degludec plus bolus insulin for at least 6 months were included. Patients had to have switched to degludec as a result of recurrent hypoglycemia and/or hypoglycemia unawareness...
March 16, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
R Roussel, R Ritzel, E Boëlle-Le Corfec, B Balkau, J Rosenstock
AIMS: To explore comparative glycaemic control and hypoglycaemia incidence with insulin degludec 100U/mL (IDeg) or insulin glargine 300U/mL (Gla-300) versus glargine 100U/mL (Gla-100) in trial-level meta-analyses of phase 3a clinical trials including people with type-2 diabetes. METHODS: Meta-analyses of HbA1c , fasting plasma glucose (FPG), average 24h self-measured plasma glucose (SMPG), pre-breakfast SMPG and hypoglycaemia incidence and rate, using data from the BEGIN (IDeg) and EDITION (Gla-300) insulin development programmes, were performed...
February 19, 2018: Diabetes & Metabolism
Martin M Grajower
Hypoglycemia is the major side effect of insulin therapy. The elderly are especially vulnerable to episodes of hypoglycemia, and with greater risks of complications such as falls. Two new long-acting basal insulins, glargine-300 (Gla-300) and degludec, are associated with lower incidences of hypoglycemia than previously available basal insulins. One of them, Gla-300, was studied in the elderly and has a lower incidence of hypoglycemia in patients over 65 years old. These new data should be incorporated into decision making when treating the elderly patient with insulin, whether they have type 1 or 2 diabetes...
March 2018: Endocrine Practice
Laura Affinito Bonabello, Davide Maggi, Samuele Fiorini, Veronica Tozzo, Renzo Cordera
No abstract text is available yet for this article.
March 10, 2018: Acta Diabetologica
Ian Blumer, Jeremy H Pettus, Tricia Santos Cavaiola
Many individuals with type 2 diabetes (T2D) will eventually require insulin therapy to help achieve and maintain adequate glycemic control. However, the use of insulin can be associated with adverse effects such as hypoglycemia and weight gain, and in some patients the addition of insulin to treatment regimens is often still insufficient to achieve target glycemic control. Combining basal insulin with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with T2D has been demonstrated to be effective and well tolerated, while mitigating many of the adverse events associated with giving either of these drug classes alone...
March 9, 2018: Postgraduate Medicine
Toshinari Asakura, Shuichi Suzuki, Toshihiko Aranishi, Zhihong Cai
OBJECTIVE: This study assessed training time with the dulaglutide single-use pen (SUP) and the insulin degludec disposable prefilled pen (FlexTouch®) in self-injection-naïve patients with type 2 diabetes mellitus (T2DM) in Japan. METHODS: This multicenter, open-label, comparative, crossover study measured training time with the dulaglutide SUP versus FlexTouch® . Participants learned how to use both devices in a randomly assigned order. Healthcare providers (HCP) conducted the training...
March 5, 2018: Current Medical Research and Opinion
Liana K Billings, Ankur Doshi, Didier Gouet, Alejandra Oviedo, Helena W Rodbard, Nikolaos Tentolouris, Randi Grøn, Natalie Halladin, Esteban Jodar
OBJECTIVE: In patients with uncontrolled type 2 diabetes on basal insulin, prandial insulin may be initiated. We assessed the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus basal-bolus insulin. RESEARCH DESIGN AND METHODS: A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart four or fewer times per day...
February 26, 2018: Diabetes Care
Dalia Dawoud, Rachel O'Mahony, David Wonderling, Jill Cobb, Bernard Higgins, Stephanie A Amiel
OBJECTIVE: To assess the relative efficacy and safety of basal insulin regimens in adults with type 1 diabetes mellitus (T1DM). METHODS: A systematic review and Bayesian network meta-analysis (NMA) of randomized controlled trials comparing two or more basal insulin regimens were conducted. The following basal insulin regimens were included: Neutral Protamine Hagedorn (iNPH) (once [od], twice [bid], and four times daily [qid]), insulin detemir (iDet) (od and bid), insulin glargine 100 IU (iGlarg) (od), and insulin degludec (iDegl) (od)...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Sarah Eggert, Esther Zimmermann, Kamilla Begtrup
No abstract text is available yet for this article.
March 5, 2018: Expert Opinion on Pharmacotherapy
Péter Judák, Peter Van Eenoo, Koen Deventer
The measurement of human insulin and its synthetic analogues in biological matrices has become increasingly important not only in clinical fields but also in doping control. The use of insulin and its analogues have been included in the list of prohibited substances published by the World Anti-Doping Agency (WADA). This study describes a qualitative method for detection of insulin analogues (lispro, aspart, glulisine, glargine, degludec, detemir) in human urine. The sample preparation consists of a preconcentration step using ultrafiltration followed by an immunoaffinity extraction with an antibody precoated ELISA plate...
February 12, 2018: Journal of Pharmaceutical and Biomedical Analysis
Martin Haluzík, Greg Fulcher, Thomas R Pieber, Lars Bardtrum, Deniz Tutkunkardas, Helena W Rodbard
AIMS: Previous studies demonstrated the co-formulation of insulin degludec (IDeg)/insulin aspart (IAsp) 'IDegAsp' offers lower rates of hypoglycaemia with smaller changes in weight compared with basal-bolus (IDeg once daily [OD] + IAsp [2-4 injections]) and premix insulin (BIAsp 30 twice daily [BID]) comparators. This study aimed to investigate whether the benefits of IDegAsp, given twice daily, extend across a wide spectrum of patients with diabetes. MATERIALS AND METHODS: This was a post hoc pooled analysis of five phase 3 randomised, 26-week, open-label, BID, treat-to-target trials comparing IDegAsp BID (n = 1111) with one of two 'comparators' - BIAsp 30 BID (n = 561) or IDeg OD + IAsp (n = 136)...
February 16, 2018: Diabetes, Obesity & Metabolism
Xiao-Wen Zhang, Xin-Lin Zhang, Biao Xu, Li-Na Kang
AIMS: To determine the safety and efficacy of insulin degludec versus glargine in patients with type 1 (T1D) and type 2 (T2D) diabetes mellitus. METHODS: Databases were searched until July 5, 2017. We included randomized controlled trials comparing degludec with glargine in diabetic patients, each with a minimum of 16 weeks of follow-up. RESULTS: Eighteen trials with 16,791 patients were included. Degludec was associated with a statistically significant reduction in risk for all confirmed hypoglycemia at the maintenance treatment period [estimated rate ratio (ERR) 0...
February 8, 2018: Acta Diabetologica
Elena Salesov, Eric Zini, Angelina Riederer, Thomas A Lutz, Claudia E Reusch
With the aim to improve current therapeutic and monitoring options for diabetic cats, the present study compared pharmacodynamic parameters of protamine zinc insulin (PZI) and insulin degludec and validated the continuous glucose monitoring system (CGMS) iPro2 with Sof-sensor and Enlite-sensor focusing on the low glycemic range. Three doses (0.1, 0.2 and 0.3IU/kg) of the two insulin preparations and the CGMS iPro2 with two different sensors were tested in six healthy cats. After each insulin administration, onset of action, time to glucose nadir and duration of action were calculated by measuring glucose concentrations with a portable blood glucose meter (PBGM)...
January 26, 2018: Research in Veterinary Science
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P Jansen, Adam Fridhammar
BACKGROUND: We assessed the cost-effectiveness of the glucagon-like peptide 1 receptor agonists liraglutide 1.8 mg and lixisenatide 20 μg (both added to basal insulin) in patients with type 2 diabetes (T2D) in Sweden. METHODS: The Swedish Institute for Health Economics cohort model for T2D was used to compare liraglutide and lixisenatide (both added to basal insulin), with a societal perspective and with comparative treatment effects derived by indirect treatment comparison (ITC)...
2018: PloS One
Steven P Marso, John B Buse
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
Riccardo Perfetti
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
John A Tayek, Paul N N Danese, Michael S Smith
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
Amie A Ogunsakin, Nidhi Jain, Samuel Dagogo-Jack
No abstract text is available yet for this article.
November 16, 2017: New England Journal of Medicine
Edurne Lecumberri, Maite Ortega, Marta Iturregui, José Antonio Quesada, Clotilde Vázquez, Domingo Orozco
OBJECTIVE: The frequency of hypoglycemia in patients with T1DM is high and results in a poorer quality of life and low treatment satisfaction. The aim of our study is to demonstrate the effect of changing the basal insulin (glargine or detemir) to insulin degludec. METHODS: We conducted an observational analytical study on a cohort of 110 patients with T1DM. The patients were administered 3 questionnaires to assess treatment satisfaction (DTSQ-s), fear of hypoglycemia (HFS-II) and quality of life (EQ-5D), before the change and at 6 months...
January 4, 2018: Current Medical Research and Opinion
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"